论文部分内容阅读
已知拉米夫定可有效地抑制病毒DNA的复制,并有很好耐受性。因此,作者观察 了拉米夫定对未作肝移植的慢性乙型肝炎后失代偿期肝硬化的治疗效果。 该研究入选的35例患者(仅1例女性)为1995年8月～1998年8月期间的连续病例,包括27例白种人、1例黑种人和7例黄种人。其中20例患者HBeAg和HBV DNA阳性,15例抗-HBe和HBV DNA阳性,2例抗-HDV阳性,2例抗-HCV阳性,1例HCV
It is known that lamivudine can effectively inhibit the replication of viral DNA and is well tolerated. Therefore, the authors looked at the efficacy of lamivudine in the treatment of decompensated cirrhosis after chronic hepatitis B without liver transplantation. The 35 patients enrolled in this study (only 1 woman) were consecutive cases between August 1995 and August 1998, including 27 Caucasian, 1 Black and 7 Yellow. 20 of them were positive for HBeAg and HBV DNA, 15 were positive for anti-HBe and HBV DNA, 2 were anti-HDV positive, 2 were anti-HCV positive and 1 was HCV